Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy

Yearbook of Dermatology and Dermatologic Surgery ◽

10.1016/j.yder.2011.09.022 ◽

2012 ◽

Vol 2012 ◽

pp. 107-108

Author(s):

J. Weinberg

Keyword(s):

Plaque Psoriasis ◽

Disease Recurrence ◽

Efficacy And Safety ◽

Faculty Opinions recommendation of Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718340215.793493941 ◽

2014 ◽

Author(s):

Kamran Ghoreschi ◽

Sebastian Volc

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Study

AN OPEN-LABELLED RANDOMISED COMPARATIVE EVALUATION OF THERAPEUTIC EFFICACY AND SAFETY OF APREMILAST VERSUS METHOTREXATE IN THE TREATMENT OF PATIENTS WITH CHRONIC PLAQUE PSORIASIS

10.36295/asro.2020.231517 ◽

2020 ◽

Vol 23 (15) ◽

Author(s):

Rathipriyadharshini R ◽

Prem Kumar M ◽

Soundarya S ◽

Srinivasan M.S

Keyword(s):

Plaque Psoriasis ◽

Therapeutic Efficacy ◽

Comparative Evaluation ◽

Efficacy And Safety ◽

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

10.1016/j.jaad.2014.01.897 ◽

2014 ◽

Vol 71 (3) ◽

pp. 484-492 ◽

Cited By ~ 49

Author(s):

D.S. Krupashankar ◽

Sunil Dogra ◽

Mahendra Kura ◽

Abir Saraswat ◽

Leelavathy Budamakuntla ◽

...

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Study

25482 Secukinumab efficacy and safety profile in pediatric patients with severe chronic plaque psoriasis up to 1 year

10.1016/j.jaad.2021.06.263 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB59

Author(s):

Christine Bodemer ◽

Andrzej Kaszuba ◽

Külli Kingo ◽

Athanasios Tsianakas ◽

Akimichi Morita ◽

...

Keyword(s):

Plaque Psoriasis ◽

Safety Profile ◽

Pediatric Patients ◽

Efficacy And Safety ◽

Efficacy and Safety of the Betamethasone Valerate 0.1% Plaster in Mild-to-Moderate Chronic Plaque Psoriasis

American Journal of Clinical Dermatology ◽

10.2165/11539780-000000000-00000 ◽

2011 ◽

Vol 12 (3) ◽

pp. 191-201 ◽

Cited By ~ 10

Author(s):

Luigi Naldi ◽

Nikhil Yawalkar ◽

Andrzej Kaszuba ◽

Jean-Paul Ortonne ◽

Paolo Morelli ◽

...

Keyword(s):

Plaque Psoriasis ◽

Betamethasone Valerate ◽

Efficacy And Safety ◽

Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet: Efficacy and Safety Results From REACH, a Randomized, Placebo-Controlled, Double-Blind Trial

Yearbook of Dermatology and Dermatologic Surgery ◽

10.1016/j.yder.2011.11.013 ◽

2012 ◽

Vol 2012 ◽

pp. 111-113

Author(s):

B.D. Michaels ◽

J.Q. Del Rosso

Keyword(s):

Plaque Psoriasis ◽

Double Blind Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Blind Trial ◽

Hands And Feet

Adalimumab efficacy and safety results in patients with moderate to severe chronic plaque psoriasis with and without psoriatic arthritis

10.1016/j.jaad.2004.10.710 ◽

2005 ◽

Vol 52 (3) ◽

pp. P174

Keyword(s):

Psoriatic Arthritis ◽

Plaque Psoriasis ◽

Efficacy And Safety ◽

Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study

The Journal of Dermatology ◽

10.1111/j.1346-8138.2009.00748.x ◽

2010 ◽

Vol 37 (4) ◽

pp. 299-310 ◽

Cited By ~ 121

Author(s):

Akihiko ASAHINA ◽

Hidemi NAKAGAWA ◽

Takafumi ETOH ◽

Mamitaro OHTSUKI ◽

Keyword(s):

Phase Ii ◽

Plaque Psoriasis ◽

Japanese Patients ◽

Randomized Controlled Study ◽

Controlled Study ◽

Efficacy And Safety ◽

Randomized Controlled

Maintenance of efficacy and safety with continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Final phase IIIb study results

10.1016/j.jaad.2004.10.020 ◽

2005 ◽

Vol 52 (3) ◽

pp. P1

Keyword(s):

Plaque Psoriasis ◽

Efficacy And Safety ◽

Final Phase ◽

Study Results ◽

Phase Iiib